Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹
Scilex Holding Company (SCLX)
Company Research
Source: GlobeNewswire
The lifetime prevalence of neck pain in the adult population is estimated to range from 14.2% to 71% with a mean of 48.5%.2 There are currently no approved medical treatments for neck pain in the U.S.The study was a randomized, double-blind, placebo-controlled crossover trial performed at four U.S. military, Veterans Administration, academic, and private practice sites, in which 76 patients were randomized to receive either a placebo patch followed by ZTlido® for 4-week intervals or vice versa.Overall, separation between ZTlido® and placebo effects and variability observed in this patient population provided necessary estimates for planning a potential Phase 3 development trial of SP-103 (triple-strength formulation of ZTlido®) which contains 3-times higher concentration of lidocaine and has completed a Phase 2 trial in acute back pain. PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating
Show less
Read more
Impact Snapshot
Event Time:
SCLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SCLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SCLX alerts
High impacting Scilex Holding Company news events
Weekly update
A roundup of the hottest topics
SCLX
News
- Scilex Holding (NASDAQ: SCLX) had its price target lowered by analysts at HC Wainwright from $12.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Scilex Holding Company Announces Closing of $15 Million Registered Direct OfferingGlobeNewswire
- Scilex Holding Company Announces $15 Million Registered Direct OfferingGlobeNewswire
- Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other AdGlobeNewswire
- Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing PoolGlobeNewswire
SCLX
Earnings
- 11/14/23 - Miss
SCLX
Sec Filings
- 4/25/24 - Form SC
- 4/25/24 - Form 424B3
- 4/25/24 - Form 424B3
- SCLX's page on the SEC website